A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle.
Treatment will continue until disease progression, or unacceptable adverse events develop